arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Zentalis Pharmaceuticals, Inc.

ZNTL Health Care Biotechnology: Pharmaceutical Preparations
$2.21
▼ -6.4% Today
as of Oct 23, 16:53 ET
Last 30 days -36.86% Sep 14 → Oct 23
$2.02 $2.42 $2.82 $3.21 $3.61 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.41
High
$2.41
Low
$2.18
Volume
$947,069
Avg Vol
$1M
Mkt Cap
$247M
P/E (TTM)
—
Beta
—
52w High
$6.95
52w Low
$1.21
Div Yield
—
Shares Out
$72M

Recent Press Releases & News last 60 days · 10 items

Oct 23 · 16:41 MT Newswires
Zentalis Pharmaceuticals Reports Survival Data for Ovarian Cancer Drug Azenosertib
Oct 23 · 14:15 PR GlobeNewswire
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
Oct 18 · 22:05 PR GlobeNewswire
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
▸ Show all 10 press releases & news Free account →

ZNTL earnings at a glance

The options market is pricing a move of about ±35.9% after the report, a range of roughly $1.42 to $3.00 from today's $2.21. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±2.5% on average; after the most recent report on May 12, 2026 it moved +3.4%. That means options currently expect more movement than ZNTL has typically delivered. ZNTL beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 304%. The share price of $2.21 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.21
$6.95
17% of range
Avg surprise (last 4)
+14.1%
Avg reaction (last 2)
+0.9%
50% positive
Latest IV / EM
304%
EM ±35.9% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.85$-1.35$-0.85$-0.36$0.14 Actual $-1.07Actual $-1.85Actual $-0.79Actual $0.14Actual $-1.24Actual $-0.56Actual $-0.67Est $-0.67Actual $-0.37Est $-0.56Actual $-0.37Est $-0.49Actual $-0.50Est $-0.49Actual $-0.59 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-48M$-43M$-38M$-33M$-28M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.59 — — — — financials
Tue May 12, 2026Mar/2026 $-0.50 $-0.49 -2.0% +25.4% +3.4% earnings
Mon Nov 10, 2025Sep/2025 $-0.37 $-0.49 +24.5% — — earnings
Wed Aug 6, 2025Jun/2025 $-0.37 $-0.56 +33.9% — — earnings
Wed May 14, 2025Mar/2025 $-0.67 $-0.67 0.0% — -1.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.56 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.24 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.14 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.79 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.85 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.07 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———$0$0$0—$0
Cost of revenue————————
Gross profit————————
Operating income$-44M$-38M—$-34M$-36M$-46M—$-51M
Net income$-42M$-35M—$-27M$-27M$-48M—$-40M
EPS (diluted)$-0.59$-0.50—$-0.37$-0.37$-0.67—$-0.56

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$25M$32M$36M$39M$38M$42M$34M$41M
Inventory————————
Total current assets$181M$218M$253M$288M$312M$343M$386M$400M
Total assets$215M$253M$289M$327M$352M$384M$430M$451M
Long-term debt————————
Total liabilities$72M$70M$73M$74M$77M$89M$93M$96M
Total equity$144M$183M$216M$253M$274M$295M$337M$354M

Implied volatility — last 90 days

83%655%1227%1799%2371% Jun 08 — IV 518% · EM ±68.4%Jun 09 — IV 424% · EM ±53.1%Jun 10 — IV 553% · EM ±65.3%Jun 11 — IV 514% · EM ±56.8%Jun 12 — IV 547% · EM ±56.0%Jun 15 — IV 1426% · EM ±103.2%Jun 16 — IV 1016% · EM ±60.0%Jun 17 — IV 2084% · EM ±87.0%Jun 19 — IV 202% · EM ±44.6%Jun 22 — IV 307% · EM ±64.0%Jun 23 — IV 319% · EM ±65.2%Jun 24 — IV 327% · EM ±65.5%Jun 25 — IV 192% · EM ±37.6%Jun 26 — IV 330% · EM ±63.1%Jun 29 — IV 138% · EM ±24.4%Jun 30 — IV 141% · EM ±24.2%Jul 01 — IV 271% · EM ±45.4%Jul 02 — IV 152% · EM ±24.7%Jul 03 — IV 158% · EM ±24.7%Jul 06 — IV 157% · EM ±21.7%Jul 07 — IV 416% · EM ±54.9%Jul 08 — IV 427% · EM ±53.5%Jul 09 — IV 122% · EM ±14.4%Jul 10 — IV 83% · EM ±9.2%Jul 13 — IV 201% · EM ±16.8%Jul 14 — IV 261% · EM ±18.9%Jul 15 — IV 930% · EM ±54.9%Jul 16 — IV 183% · EM ±7.7%Jul 20 — IV 124% · EM ±29.4%Jul 21 — IV 120% · EM ±27.9%Jul 22 — IV 173% · EM ±39.7%Jul 23 — IV 117% · EM ±26.4%Jul 24 — IV 141% · EM ±31.2%Jul 27 — IV 308% · EM ±64.3%Jul 28 — IV 300% · EM ±61.4%Jul 29 — IV 281% · EM ±56.2%Jul 30 — IV 283% · EM ±55.4%Jul 31 — IV 110% · EM ±21.1%Aug 03 — IV 127% · EM ±22.6%Aug 04 — IV 140% · EM ±24.1%Aug 05 — IV 94% · EM ±15.7%Aug 06 — IV 105% · EM ±17.0%Aug 07 — IV 326% · EM ±50.9%Aug 10 — IV 339% · EM ±47.0%Aug 11 — IV 636% · EM ±83.9%Aug 12 — IV 353% · EM ±44.3%Aug 13 — IV 927% · EM ±109.5%Aug 14 — IV 541% · EM ±59.8%Aug 17 — IV 501% · EM ±41.8%Aug 18 — IV 563% · EM ±40.8%Aug 19 — IV 1618% · EM ±95.6%Aug 20 — IV 2089% · EM ±87.2%Aug 24 — IV 245% · EM ±51.2%Aug 25 — IV 124% · EM ±25.5%Aug 26 — IV 257% · EM ±51.4%Aug 27 — IV 286% · EM ±56.1%Aug 28 — IV 296% · EM ±56.6%Aug 31 — IV 563% · EM ±99.7%Sep 01 — IV 542% · EM ±93.2%Sep 02 — IV 580% · EM ±96.8%Sep 03 — IV 356% · EM ±57.6%Sep 04 — IV 560% · EM ±87.6%Sep 07 — IV 642% · EM ±89.0%Sep 08 — IV 648% · EM ±85.6%Sep 09 — IV 347% · EM ±43.4%Sep 10 — IV 802% · EM ±94.7%Sep 11 — IV 941% · EM ±104.0%Sep 14 — IV 1285% · EM ±107.3%Sep 15 — IV 1391% · EM ±100.6%Sep 16 — IV 1802% · EM ±106.5%Sep 17 — IV 2371% · EM ±99.0%Sep 21 — IV 199% · EM ±41.5%Sep 22 — IV 206% · EM ±42.2%Sep 23 — IV 174% · EM ±34.8%Sep 24 — IV 176% · EM ±34.5%Sep 25 — IV 213% · EM ±40.7%Sep 28 — IV 233% · EM ±41.2%Sep 29 — IV 288% · EM ±49.6%Oct 08 — IV 304% · EM ±35.9%

Sector peers

QTTB
Q32 Bio Inc.
$246M $8.65-0.2%
AKBA
Akebia Therapeutics, Inc.
$241M $0.57-3.1%
IFRX
InflaRx N.V.
$252M $1.56+0.7%
AMRN
Amarin Corporation plc
$254M $11.79+2.4%
SLGL
Sol-Gel Technologies Ltd.
$238M $69.45+5.7%
SIGA
SIGA Technologies Inc.
$234M $3.120.0%

ZNTL earnings FAQ

What is ZNTL's expected move for earnings?

Options currently price a move of about ±35.9%, or $0.79 per share either way from $2.21.

How does ZNTL stock usually react to earnings?

Across the last 2 reports the average next-day move was ±2.5%, up 1 times and down 1 times.

What is ZNTL's implied volatility?

ZNTL's at-the-money implied volatility is about 304% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in